TORNTPHARM Stock Overview
Engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Brazil, Germany, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Torrent Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹3,202.95 |
| 52 Week High | ₹3,590.70 |
| 52 Week Low | ₹2,025.70 |
| Beta | 0.26 |
| 11 Month Change | -0.39% |
| 3 Month Change | -8.10% |
| 1 Year Change | 50.62% |
| 33 Year Change | 115.60% |
| 5 Year Change | 241.84% |
| Change since IPO | 26,591.25% |
Recent News & Updates
Earnings Miss: Torrent Pharmaceuticals Limited Missed EPS By 7.7% And Analysts Are Revising Their Forecasts
Oct 29
Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) Popularity With Investors Is Under Threat From Overpricing
Oct 24Recent updates
Earnings Miss: Torrent Pharmaceuticals Limited Missed EPS By 7.7% And Analysts Are Revising Their Forecasts
Oct 29Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) Popularity With Investors Is Under Threat From Overpricing
Oct 24Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Just Reported And Analysts Have Been Lifting Their Price Targets
Jul 26Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) P/E Is On The Mark
Apr 16Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?
Mar 03Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Increasing Its Dividend To ₹22.00
Feb 05Investors Interested In Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) Earnings
Jan 07Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Rather Sparingly
Nov 14Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jun 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Mar 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jul 25Torrent Pharmaceuticals' (NSE:TORNTPHARM) Soft Earnings Don't Show The Whole Picture
Jun 02Estimating The Fair Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)
May 25A Look At The Intrinsic Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)
Feb 18Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Increasing Its Dividend To ₹25.00
Jan 27Here's Why Torrent Pharmaceuticals (NSE:TORNTPHARM) Can Manage Its Debt Responsibly
Jan 04Here's Why I Think Torrent Pharmaceuticals (NSE:TORNTPHARM) Is An Interesting Stock
Dec 14A Look At The Fair Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)
Nov 07Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Sep 30Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Deserve A Spot On Your Watchlist?
Sep 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jul 02I Ran A Stock Scan For Earnings Growth And Torrent Pharmaceuticals (NSE:TORNTPHARM) Passed With Ease
Jun 01Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Shares Could Be 30% Above Their Intrinsic Value Estimate
May 14Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?
Mar 23Shareholder Returns
| TORNTPHARM | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 3.3% | 0.8% | 2.9% |
| 1Y | 50.6% | 42.1% | 28.9% |
Return vs Industry: TORNTPHARM exceeded the Indian Pharmaceuticals industry which returned 42.1% over the past year.
Return vs Market: TORNTPHARM exceeded the Indian Market which returned 28.9% over the past year.
Price Volatility
| TORNTPHARM volatility | |
|---|---|
| TORNTPHARM Average Weekly Movement | 3.6% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: TORNTPHARM has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: TORNTPHARM's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1959 | 15,718 | Samir Mehta | www.torrentpharma.com |
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Brazil, Germany, and internationally. The company offers products in various therapeutic areas, including cardiovascular, central nervous system, gastro-intestinal, and women healthcare; and dermatology, diabetology, pain management, gynecology, oncology, and anti-infective, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services.
Torrent Pharmaceuticals Limited Fundamentals Summary
| TORNTPHARM fundamental statistics | |
|---|---|
| Market cap | ₹1.08t |
| Earnings (TTM) | ₹18.02b |
| Revenue (TTM) | ₹112.24b |
60.2x
P/E Ratio9.7x
P/S RatioIs TORNTPHARM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TORNTPHARM income statement (TTM) | |
|---|---|
| Revenue | ₹112.24b |
| Cost of Revenue | ₹27.48b |
| Gross Profit | ₹84.76b |
| Other Expenses | ₹66.73b |
| Earnings | ₹18.02b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 53.25 |
| Gross Margin | 75.51% |
| Net Profit Margin | 16.06% |
| Debt/Equity Ratio | 40.6% |
How did TORNTPHARM perform over the long term?
See historical performance and comparison